Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2

被引：0
|
作者：
Arribas, Alberto J.
Cascione, Luciano
Cannas, Eleonora
Bellerjeau, Helen
Fuzio, Federica
Noguera, Aleix
Rinaldi, Andrea
Esteller, Manel
Zucca, Emanuele
Alimonti, Andrea
Rossi, Davide
Stathis, Anastasios
Bertoni, Francesco
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
534
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
    Qian, Xiao-jun
    Li, Yun-tian
    Yu, Yan
    Yang, Fen
    Deng, Rong
    Ji, Jiao
    Jiao, Lin
    Li, Xuan
    Wu, Rui-Yan
    Chen, Wen-Dan
    Feng, Gong-Kan
    Zhu, Xiao-Feng
    ONCOTARGET, 2015, 6 (07) : 5134 - 5146
  • [22] IN VIVO AND IN VITRO EFFICACY OF DUAL PI3K/MTOR INHIBITION IN NOVEL MURINE MODELS OF ANAL CANCER.
    Rademacher, B.
    Lim, A.
    Sleiman, H.
    Micka, J.
    Culberson, W.
    Romero, A.
    Meske, L.
    Carchman, E.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E94 - E95
  • [23] Mechanisms of secondary resistance to dual PI3K/mTOR inhibition in sarcomas with complex genetics
    Fourneaux, Benjamin
    Bourdon, Aurelien
    Chaire, Vanessa
    Lucchesi, Carlo
    Karanian, Marie
    Pineau, Raphael
    Laroche, Audrey
    Italiano, Antoine
    CANCER RESEARCH, 2017, 77
  • [24] Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
    Kumar, Anshul
    Bhatia, Rohit
    Chawla, Pooja
    Anghore, Durgadas
    Saini, Vipin
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (10) : 1158 - 1172
  • [25] Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins
    Mukherjee, R.
    Vanaja, K. Gireesan
    Sharma, M.
    Solomon, H.
    De Stanchina, E.
    Chandarlapaty, S.
    Rosen, N.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
  • [26] Tackling Resistance to PI3K Inhibition by Targeting the Epigenome
    Koren, Shany
    Bentires-Alj, Mohamed
    CANCER CELL, 2017, 31 (05) : 616 - 618
  • [27] PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
    Gopal, Ajay K.
    Kahl, Brad S.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Schuster, Stephen J.
    Jurczak, Wojciech J.
    Flinn, Ian W.
    Flowers, Christopher R.
    Martin, Peter
    Viardot, Andreas
    Blum, Kristie A.
    Goy, Andre H.
    Davies, Andrew J.
    Zinzani, Pier Luigi
    Dreyling, Martin
    Johnson, Dave
    Miller, Langdon L.
    Holes, Leanne
    Li, Daniel
    Dansey, Roger D.
    Godfrey, Wayne R.
    Salles, Gilles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11): : 1008 - 1018
  • [28] MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
    Lee, J. Scott
    Tang, Sarah S.
    Ortiz, Veronica
    Thanh-Trang Vo
    Fruman, David A.
    ONCOTARGET, 2015, 6 (34) : 35202 - 35217
  • [29] Vertical inhibition of the PI3K pathway potently sensitizes diffuse large B cell lymphoma to BCL-2 antagonism
    Lee, Jong-Hoon Scott
    Tang, Sarah
    Ortiz, Veronica
    Fruman, David A.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [30] Inhibition of miR-4763-3p expression activates the PI3K/mTOR/Bcl2 autophagy signaling pathway to ameliorate cognitive decline
    Qi, Wenxin
    Ying, Yiwei
    Wu, Peiru
    Dong, Naijun
    Fu, Wenjun
    Liu, Qian
    Ward, Natalie
    Dong, Xin
    Zhao, Robert Chunhua
    Wang, Jiao
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2024, 20 (15): : 5999 - 6017
12345